FAFernando Argento

Fernando Argento

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fernando Argento has a total of 92 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Content validity of the modified EQ-HWB-9 in a sample of Argentinean patients, informal caregivers, and members of the general public

    by Maria Belizan, Natalí Ini, Fernando Argento, Michael Herdman, Clara Mukuria, Federico Augustovski

    In response to the challenge of measuring the impact of health, social care, and informal caregiving on quality of life, the EuroQol Group developed the Experimental EuroQol Health and Wellbeing (EQ-HWB-9). Evidence from preliminary testing informed a series of revisions to improve the instrument's performance. This study aimed to assess the content validity of the Argentina (Spanish) EQ-HWB-9 Experimental Modified Paper Self-Complete v1.2 (modified EQ-HWB-9), to explore whether its modifications represented an improvement over the earlier experimental version, and to examine how participants ranked the frequency scale response options. Qualitative cognitive interviews were conducted using a semi-structured guide with open-ended questions and targeted probes to assess comprehensibility, relevance, and comprehensiveness of the modified EQ-HWB-9. Participants were recruited through purposive sampling via patient associations, retirement centers, and social media. Thematic content analysis was guided by an a priori framework. Participants also completed a response option ordering exercise to compare their rankings with the instrument's frequency scale. Twenty participants were included: patients (n = 12), informal carers (n = 4), and members of the general public (n = 4); nine were also social care users. The median age was 64.5 years (range 25-88) and 12 were women. All participants found the questionnaire easy to understand, items were deemed relevant, and response options appropriate. Some participants noted missing content related to leisure, social relationships, financial situation, and environment, and suggested minor wording revisions. The modified EQ-HWB-9 was generally preferred over the earlier version, supporting better comprehension and alignment with local language and context. In the frequency scale task, "none of the time" and "most or all of the time" were consistently placed at the expected extremes (90% and 85%, respectively), while intermediate labels showed greater variability, with overall ordering showing good alignment with the instrument's scale. This study, conducted as part of an international multi-language effort, represents the first content validity assessment of the modified EQ-HWB-9 in Spanish and Latin America. Findings support the instrument's utility, though further refinements to item wording are recommended. Ongoing iterative testing will help ensure the tool reliably measures health and wellbeing to inform policy and practice.

  • Open Access

    PP95 Conceptual Mapping Of Health-Related Quality Of Life, Quality Of Life, And Well-Being: A Systematic Review

    by Fernando Argento, Federico Augustovski, Maria Belizan, Natali Ini

    Introduction: Assessing health-related quality of life (HRQoL), quality of life (QoL), and well-being (WB) are essential for measuring health outcomes. This study provided a conceptual mapping of these measures, proposed evidence-based frameworks, and linked them to widely used generic patient-reported outcome measures. Methods: A systematic literature review was conducted that included articles from databases and gray literature through to December 2023. Studies describing HRQoL, QoL, and WB concepts with their dimensions or domains were included, focusing on general population studies without design restrictions. Domains, subdomains, and facets were extracted and analyzed based on frequency and qualitative methods. These frameworks were then mapped to commonly used generic patient-reported outcome measures. Results: From 14,114 papers, 35 studies and 36 frameworks were included (HRQol=15, Qol=5, WB=16). A total of 168 first, 225 second, and 79 third-level domains were retrieved and curated into 118 unique entities: HRQoL had 82 dimensions, QoL had 49, and WB had 69. Overlap analysis revealed 26 shared dimensions, with 26 unique to WB, 29 to HRQoL, and seven to QoL. Final models included 18 HRQoL, 22 QoL (18 from HRQoL plus 4), and 10 WB dimensions. Mapping of patient-reported outcome measures showed coverage for HRQoL of 59.4 percent, QoL of 65.9 percent, and WB of 34 percent. The EuroQol Health and Wellbeing instrument had the broadest coverage for HRQoL (17/18) and WB (5/10). Conclusions: Significant inconsistencies and overlaps exist among definitions and domains for HRQoL, QoL, and WB. The lack of clear conceptual and operational definitions hinders the validity of measurement tools. This study underscored the need for clearer definitions and provided an initial step toward better understanding and measurement of these essential health and policy concepts.


  • Open Access

    A Delphi study on valuing DNA sequencing in oncology: a European stakeholder developed framework for assessing next generation sequencing and comprehensive genomic profiling diagnostics

    by Augustovski Federico, Chavez Danitza, Haig Madeleine, Main Caitlin, Argento Fernando, Colaci Carla, Mills Mackenzie, Alfie Verónica, Pichon-Riviere Andrés, Alcaraz Andrea, et al.

  • Immunogenicity of COVID-19 Vaccines During Pregnancy: A Systematic Review and Comparison of Pregnant Versus Nonpregnant Persons

    by Jamile Ballivian, Edward P.K. Parker, Mabel Berrueta, Agustín Ciapponi, Fernando Argento, Ariel Bardach, Martin Brizuela, Noelia Castellana, Daniel Comande, Beate Kampmann, et al.

    Background: The COVID-19 pandemic induced the rapid deployment of novel vaccines with pregnant persons identified as an at-risk population due to their increased risk of severe outcomes. Limited data on the immunogenicity of COVID-19 vaccines in pregnant persons were available at the time of implementation. To address this data gap, we developed a living systematic review summarizing emerging evidence on vaccine immunogenicity in pregnancy. Methods: Following Cochrane, World Health Organization, and Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines, we included studies on COVID-19 vaccines during pregnancy. We carried out comprehensive biweekly literature searches from March 2022 to October 2023, covering multiple databases. Study selection, data extraction and risk of bias assessment were conducted by pairs of authors independently. Immunogenicity outcomes, primarily post-vaccination neutralizing or binding antibody concentrations, were analyzed descriptively. Post-vaccination antibody ratios in pregnant versus nonpregnant individuals were calculated for the subset of studies that included nonpregnant comparators. Results: By October 2023, our review encompassed 62 studies predominantly analyzing maternal sera (87%), with limited investigation regarding cord, neonatal and infant sera. Most studies investigated mRNA vaccines (97%) and focused on primary vaccination (82%), with some investigating booster doses (15%). Immunogenicity end points included spike-specific IgG (84%) and neutralizing antibodies (24%), with limited data on T-cell responses (3%). Antibodies were detectable after primary vaccination in most pregnant individuals, with similar or modestly attenuated concentrations compared to nonpregnant individuals (ratios > 0.7 for 5/6 estimates of spike-specific IgG), albeit with modest differences in antibody quality and kinetics. Long-term antibody-waning trajectories were similar between pregnant and nonpregnant individuals for up to 8 months after vaccination. Conclusions: mRNA COVID-19 vaccines induce a robust antibody response during pregnancy comparable (or modestly attenuated) relative to nonpregnant individuals. Immunogenicity data on non-mRNA vaccines are notably underrepresented in the existing literature.


  • Budget impact of low-dose computed tomography screening for lung cancer in Argentina

    by Constanza Silvestrini, Lucas Perelli, Andrea Alcaraz, Natalia Espinola, Fernando Argento

    Lung cancer (LC) is a leading cause of cancer mortality in Argentina. Low-dose computed tomography (LDCT) had demonstrated higher efficacy than chest radiography as a screening method for early detection and reducing LC mortality. This study estimates the Budget Impact of implementing annual LDCT screening for individuals aged 55-74 with at least 30 pack-years of smoking in Argentina. A budgetary impact model for a dynamic cohort was developed from the Argentine health system's perspective, accounting for LC incidents, prevalents and death probability, distinguishing by disease stage and survival years. Model parameters were sourced from literature and official databases, with costs expressed in 2023 USD. In Argentina, 726,420 individuals were eligible for annual LC screening. The average annual budget was USD 196,611,452 in the current scenario and USD 207,439,560 in the projected scenario, leading to a 5.20% incremental cost due to more false positives in LDCT and screening costs. The budget impact per member per month was USD 0.019, slightly above the estimated threshold of USD 0.015. The introduction of LDCT for LC screening increased the health system budget in Argentina but improved early disease detection.


  • Open Access

    Budget Impact Analysis of Olaparib in Combination with Bevacizumab for Maintenance Therapy for Ovarian Cancer in Argentina

    by Carlos Rojas-Roque, Constanza Silvestrini, Fernando Argento, Daniela Sugg, Federico Augustovski, Jesica Coelli, Natalia Espinola

    Objectives To perform a budget impact analysis (BIA) of introducing olaparib as maintenance therapy in women who have BRCA mutations (BRCAm) with platinum-sensitive recurrent ovarian cancer (PSROC) in combination with bevacizumab in Argentina. Methods A BIA model was used to analyse over a 5-year time horizon the change in the health system’s budget following the adoption of olaparib as maintenance therapy in BRCAm patients with PSROC. The BIA for each year was estimated by comparing the cost difference between the current scenario (treatment with bevacizumab) and the new scenario (the addition of olaparib) for a third-party payer. The BIA is estimated at the national health system level, and by healthcare sectors in Argentina (public sector, social security and private sector). International and national epidemiological data were used to determine the target patient population. Clinical efficacy, safety outcomes and duration of treatments were obtained from the pivotal clinical study report. Relevant direct medical costs were obtained from public data in Argentina and expert consultation. All the costs are reported in US dollars as of October 2022 ($1 = 152.59 Argentine pesos). A scenario analysis assessed the full coverage of the homologous recombination deficiency (HRD) test in Argentina. In addition, one-way sensitivity analysis was conducted to evaluate the model robustness. Results For a third-party payer with a cohort of 1,000,000 women covered, the estimated target population was 2 individuals in year 1 and 6 individuals in year 5. The incorporation of olaparib, with a wholesale price per pack of $3176.32, was associated with a weighted average of the budget impact per member per month (PMPM) of $0.062 for the national health system, being above the estimated health system budget impact threshold ($0.0153). By healthcare sector, the results of budget impact PMPM for year 5 ranged between $0.08 (public sector) and $0.114 (private sector). For all perspectives, the variables that most influenced the budget impact was the incidence of ovarian cancer, the drug acquisition cost and the treatment duration. Conclusions The introduction of olaparib for the treatment of BRCAm women with PSROC has a high budget impact for all three health systems in Argentina.

  • Open Access

    Trastuzumab-emtansine versus other anti-HER2 regimens in early or unresectable or metastatic HER2 positive breast cancer: systematic review and network meta-analysis

    by Agustín Ciapponi, Ariel Bardach, Carla Colaci, Federico Rodríguez Cairoli, Fernando Argento, Ernesto Korbenfeld, Sebastián García Martí

    Objective. We aimed to study the efficacy and safety of trastuzumab-emtansine (T-DM1) versus other anti-HER2therapies in HER2+ breast cancer (BC). Materials and Methods. We performed a network meta-analysis (NMA) of randomized controlled trials (RCTs). Our study focused on patients undergoing treatment for unresectable locally advanced breast cancer (LABC) or metastatic breast cancer (mBC), which included regimens involving trastuzumab and taxanes. Additionally, we considered cases within the first 6 months of treatment for HER2+ early breast cancer (EBC). Results. A total of 23 RCTs and 41 reports were included in our analysis. LABC and mBC showed no statistically significant difference in any of the comparisons of T-DM1 versus the other anti-HER2+ therapies. When assessing progression-free survival (PFS), trastuzumab-deruxtecan (T-DXd) and PyroCap demonstrated greater efficacy compared to other treatments (Hazard Ratio [HR]: 3.57; 95% confidence interval [CI]: 2.75-4.63 and HR: 1.82; 95% CI: 1.35-2.44;respectively), while T-DM1 alone exhibited superior effectiveness compared to LapCap (HR: 0.65; 95% CI: 0.55-0.77), TrasCap (HR: 0.65; 95% CI: 0.46-0.91), LapCapCitu (HR: 0.60; 95% CI: 0.33-1.10), Nera (HR: 0.55; 95% CI: 0.39-0.77), and Cap (HR: 0.37; 95% CI: 0.28-0.49). Conclusions. NMA allows a ranking based on the comparative efficacy and safety among the interventions available. Although superior to other schemes, T-DM1 showed a lower efficacy performancein PFS and overall response rate and a trend towards worse overall survival than T-DXd.


  • Open Access

    Publisher Correction: cost-effectiveness of COVID-19 vaccination in Latin America and the Caribbean: an analysis in Argentina, Brazil, Chile, Colombia, Costa Rica, Mexico, and Peru

    by Federico Augustovski, Ariel Bardach, Adrián Santoro, Federico Rodriguez-Cairoli, Alejandro López-Osornio, Fernando Argento, Maissa Havela, Alejandro Blumenfeld, Jamile Ballivian, Germán Solioz, et al.

  • Top Cited Papers
    Open Access

    Safety of COVID-19 vaccines during pregnancy: A systematic review and meta-analysis

    by Agustín Ciapponi, Mabel Berrueta, Edward P.K. Parker, Ariel Bardach, Agustina Mazzoni, Steven A. Anderson, Fernando J. Argento, Jamile Ballivian, Karin Bok, Daniel Comandé, et al.